CITATION REPORT List of articles citing

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

DOI: 10.1073/pnas.2009799117 Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16587-16595.

Source: https://exaly.com/paper-pdf/76792382/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper IF	Citations
780	Oral SARS-CoV-2 Inoculation Establishes Subclinical Respiratory Infection with Virus Shedding in Golden Syrian Hamsters. 2020 , 1, 100121	61
779	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. 2020 , 586, 560-566	299
778	High Potency of a Bivalent Human V Domain in SARS-CoV-2 Animal Models. 2020 , 183, 429-441.e16	67
777	COVID-19 Vaccine: A comprehensive status report. 2020 , 288, 198114	380
776	Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. 2020 , 9, 2433-2445	86
775	A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19. 2020 , 2, 1-8	5
774	REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. 2020 , 370, 1110-1115	330
773	Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection. 2020 , 8,	25
772	Susceptibility of tree shrew to SARS-CoV-2 infection. 2020 , 10, 16007	57
771	SARS-CoV-2 vaccines in development. 2020 , 586, 516-527	961
770	Animal models for COVID-19. 2020 , 586, 509-515	377
769	Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters. 2020 , 12,	112
768	Lessons for COVID-19 Immunity from Other Coronavirus Infections. 2020 , 53, 248-263	180
767	STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. 2020 , 11, 5838	122
766	Nanomedicine & Nanotoxicology Future Could Be Reshaped Post-COVID-19 Pandemic. 2020 , 2,	3
765	The Assessment of Convalescent Plasma Efficacy against COVID-19. 2020 , 1, 66-77	14
764	SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. 2020 , 370, 1464-1468	3 517

(2020-2020)

763	Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. 2020 , 28, 465-474.e4		106
762	Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 29832-29838	11.5	57
761	Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. 2020 , 20, 727-738		56
760	COVID-19-Lessons Learned and Questions Remaining. 2021 , 72, 2225-2240		34
759	Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. 2020 , 370, 1227-1230		68o
758	Animal models for SARS-CoV-2 research: A comprehensive literature review. 2021 , 68, 1868-1885		28
757	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. 2020 , 26, 1694-1700		176
756	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. 2020 , 13,		26
755	Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. 2020 , 183, 1013-1023.e13		145
754	SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. 2020 , 27, 962-973.e7		136
753	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. 2020 , 12,		32
75²	Facial Masking for Covid-19 - Potential for "Variolation" as We Await a Vaccine. 2020 , 383, e101		133
75 ¹	Standardization of Reporting Criteria for Lung Pathology in SARS-CoV-2-infected Hamsters: What Matters?. 2020 , 63, 856-859		32
75°	Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice. 2020 , 12,		9
749	Risk of transmission of severe acute respiratory syndrome coronavirus 2 by transfusion: A literature review. 2020 , 60, 3046-3054		24
748	A single dose of recombinant VSV- L -spike vaccine provides protection against SARS-CoV-2 challenge. 2020 , 11, 6402		102
747	High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme. 2020 , 10, 22370		46
746	An Overview of SARS-CoV-2 and Animal Infection. 2020 , 7, 596391		56

745	A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters. 2020 , 11, 614256	25
744	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. 2020 , 8,	38
743	The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection. 2020 , 33, 108488	40
742	Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. 2020 , 9, 2673-2684	91
741	Lightening the viral load to lessen covid-19 severity. 2020 , 371, m4763	8
740	Comparison of Rapid Antigen Tests for COVID-19. 2020 , 12,	65
739	Intensive diagnostic management of coronavirus disease 2019 (COVID-19) in academic settings in Japan: challenge and future. 2020 , 40, 38	2
738	SARS-CoV-2 viability under different meteorological conditions, surfaces, fluids and transmission between animals. 2021 , 192, 110293	12
737	Predicting susceptibility for SARS-CoV-2 infection in domestic and wildlife animals using ACE2 protein sequence homology. 2021 , 40, 79-85	9
736	Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2. 2021 , 287, 113995	18
735	COVID-19: Does the infectious inoculum dose-response relationship contribute to understanding heterogeneity in disease severity and transmission dynamics?. 2021 , 146, 110431	35
734	Low-dose and oral exposure to SARS-CoV-2 may help us understand and prevent severe COVID-19. 2021 , 103, 37-41	5
733	Establishment of an African green monkey model for COVID-19 and protection against re-infection. 2021 , 22, 86-98	91
732	Reverse Zoonosis of COVID-19: Lessons From the 2009 Influenza Pandemic. 2021 , 58, 234-242	8
731	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. 2021 , 35, 74-102	7
730	A patient infected with SARS-CoV-2 over 100 days. 2021 , 114, 47-49	3
729	Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in litro approaches. 2021 , 538, 137-144	8
728	The art of the possible in approaching efficacy trials for COVID19 convalescent plasma. 2021 , 102, 244-246	6

727	SARS-CoV-2 infection of Chinese hamsters (Cricetulus griseus) reproduces COVID-19 pneumonia in a well-established small animal model. 2021 , 68, 1075-1079	30
726	A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19.	Ο
725	BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2. 2021 ,	5
724	CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.	2
723	Prior SARS-CoV-2 Infection Prevents Acute Disease and Lung Pathology in Reinfected Syrian Hamsters but not Virus Replication in the Upper Respiratory Tract.	1
722	Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. 2021 , 10, 1790-1806	18
721	A Meta-Analysis of Rhesus Macaques (), Cynomolgus Macaques (), African green monkeys (), and Ferrets () as Large Animal Models for COVID-19. 2021 , 71, 433-441	0
720	SARS-CoV-2 Causes a Systemically Multiple Organs Damages and Dissemination in Hamsters. 2020 , 11, 618891	19
719	Impact of Prior Infection on Protection and Transmission of SARS-CoV-2 in Golden Hamsters.	
718	Lipid nanoparticle formulation of niclosamide (nano NCM) effectively inhibits SARS-CoV-2 replication. 2021 , 4, 724-737	5
718 717		5
	replication. 2021 , 4, 724-737 Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a	5 8
717	Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review. 2021 , 13, 17562872211046794 mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells	
717 716	Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review. 2021, 13, 17562872211046794 mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge. 2021, Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough	8
717 716 715	Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review. 2021, 13, 17562872211046794 mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge. 2021, Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing.	8
717 716 715	Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review. 2021, 13, 17562872211046794 mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge. 2021, Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing. SARS-CoV-2 in animals: From potential hosts to animal models. 2021, 110, 59-102 Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2	2
717 716 715 714 713	Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review. 2021, 13, 17562872211046794 mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge. 2021, Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing. SARS-CoV-2 in animals: From potential hosts to animal models. 2021, 110, 59-102 Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. 2020, 11, 618685 Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of	8 2 12 29

709 Preclinical Study of DNA Vaccines Targeting SARS-CoV-2.

708	Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. 2021 ,		5
707	Drivers of Infectious Disease Seasonality: Potential Implications for COVID-19. 2021 , 36, 35-54		21
706	Roborovski hamster strain SH101 as a systemic infection model of SARS-CoV-2. 2021 , 12, 2430-2442		4
705	Seroprevalence of SARS-CoV-2 (COVID-19) exposure in pet cats and dogs in Minnesota, USA. 2021 , 12, 1597-1609		17
704	Niclosamide Inhalation Powder Made by Thin-Film Freezing: Pharmacokinetic and Toxicology Studies in Rats and Hamsters.		3
703	Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	56
702	Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. 2021 , 10, 1284-1292		13
701	Deciphering the Mechanisms of COVID-19 Induced Anosmia.		
700	Toward control of severe acute respiratory syndrome coronavirus 2 disease (COVID-19). 2021 ,		
699	The role for pre-operative CT chest scans in suspected COVID-19 patients requiring emergent surgery. 2021 , 37, 256-260		
698	Access to personal protective equipment in exposed healthcare workers and COVID-19 illness, severity, symptoms and duration: a population-based case-control study in six countries. 2021 , 6,		21
697	Fatal neuroinvasion of SARS-CoV-2 in K18-hACE2 mice is partially dependent on hACE2 expression. 2021 ,		16
696	Review of infective dose, routes of transmission and outcome of COVID-19 caused by the SARS-COV-2: comparison with other respiratory viruses. 2021 , 149, e96		39
695	Development of Corona-virus-disease-19 Vaccines. 2021 , 4, 187-190		О
694	Inactivation and Elimination of SARS-CoV-2 in Biosamples Using Simple Fixatives and Ultrafiltration. 2021 , 4,		4
693	A novel glucocorticoid and androgen receptor modulator reduces viral entry and innate immune inflammatory responses in the Syrian Hamster model of SARS-CoV-2.		1
692	Making sense of spike D614G in SARS-CoV-2 transmission. 2021 , 64, 1062-1067		4

691	Live attenuated SARS-CoV-2 vaccine candidate: Protective immunity without serious lung lesions in Syrian hamsters.	2
690	Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. 2021 ,	5
689	Host Diversity and Potential Transmission Pathways of SARS-CoV-2 at the Human-Animal Interface. 2021 , 10,	14
688	Long-term sero-positivity for IgG, sequelae of respiratory symptoms, and abundance of malformed sperms in a patient recovered from severe COVID-19. 2021 , 40, 1559-1567	4
687	Longitudinal Metabolomics of Human Plasma Reveals Robust Prognostic Markers of COVID-19 Disease Severity. 2021 ,	8
686	COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development. 2021 , 35, e21409	27
685	Potential mechanisms of action of convalescent plasma in COVID-19. 2021 , 8, 413-420	5
684	Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins. 2021 , 17, e1009282	23
683	Identification of COVID-19 prognostic markers and therapeutic targets through meta-analysis and validation of Omics data from nasopharyngeal samples.	
682	SARS CoV-2 Spike Protein Interaction With ACE2 Receptors From Wild and Domestic Species. 2021 , 12, 571707	7
681	Transmission of SARS-CoV-2 in domestic cats imposes a narrow bottleneck. 2021 , 17, e1009373	46
680	Disruption of nuclear architecture as a cause of COVID-19 induced anosmia. 2021 ,	8
679	Comparative infectivity and pathogenesis of emerging SARS-CoV-2 variants in Syrian hamsters.	13
678	Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques. 2021 , 554, 97-105	14
677	SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters. 2021 , 4,	24
676	Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. 2021 , 32, 100734	65
675	Regeneration Profiles of Olfactory Epithelium after SARS-CoV-2 Infection in Golden Syrian Hamsters. 2021 , 12, 589-595	17
674	In Vitro and In Vivo Models for Studying SARS-CoV-2, the Etiological Agent Responsible for COVID-19 Pandemic. 2021 , 13,	23

673	Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model. 2021 , 24, 102054	50
672	Evaluation of Analytical Performance of Seven Rapid Antigen Detection Kits for Detection of SARS-CoV-2 Virus. 2021 , 14, 435-440	19
671	New Insights Into the Physiopathology of COVID-19: SARS-CoV-2-Associated Gastrointestinal Illness. 2021 , 8, 640073	23
670	Phodopus roborovskii SH101 as a systemic infection model of SARS-CoV-2.	
669	Development and pre-clinical evaluation of Newcastle disease virus-vectored SARS-CoV-2 intranasal vaccine candidate.	O
668	Role of high-dose exposure in transmission hot zones as a driver of SARS-CoV-2 dynamics. 2021 , 18, 20200916	5 4
667	Characterisation of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV2 variants.	1
666	A Comprehensive Analysis of Maternal and Newborn Disease and Related Control for COVID-19. 2021 , 3, 1-23	5
665	Exposure to SARS-CoV-2 within the household is associated with greater symptom severity and stronger antibody responses in a community-based sample of seropositive adults. 2021 ,	O
664	Quantitative proteomics of hamster lung tissues infected with SARS-CoV-2 reveal host-factors having implication in the disease pathogenesis and severity.	
663	Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domain.	2
662	Sequence analysis of Indian SARS-CoV-2 isolates shows a stronger interaction of mutant receptor-binding domain with ACE2. 2021 , 104, 491-500	3
661	Animal Hosts and Experimental Models of SARS-CoV-2 Infection. 2021 , 66, 8-16	7
660	A Review of the Progress of COVID-19 Vaccine Development.	1
659	Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters. 2021 , 6, 47	19
658	Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient. 2021 ,	2
657	Wuhan to World: The COVID-19 Pandemic. 2021 , 11, 596201	39
656	Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster. 2021 , 6, 136	25

655	Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies. 2021 , 53, 498-512	4
654	Exploration and validation of related hub gene expression during SARS-CoV-2 infection of human bronchial organoids. 2021 , 15, 18	3
653	Introductions and evolutions of SARS-CoV-2 strains in Japan.	2
652	Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2. 2021 , 102,	21
651	Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model. 2021 , 17, e1009383	10
650	Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. 2021 , 54, 557-570.e5	84
649	Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. 2021 , 185, 80-90	17
648	3D visualization of SARS-CoV-2 infection and receptor distribution in Syrian hamster lung lobes display distinct spatial arrangements.	2
647	Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease. 2021 , 6, 39	21
646	Naturally-acquired immunity in Syrian Golden Hamsters provides protection from re-exposure to emerging heterosubtypic SARS-CoV-2 variants B.1.1.7 and B.1.351.	2
645	Use of convalescent serum reduces severity of COVID-19 in nonhuman primates. 2021 , 34, 108837	13
644	Household transmission of SARS-CoV-2 from humans to pets in Washington and Idaho: burden and risk factors 2022 ,	3
643	Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants. 2021,	6
642	A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model. 2021 , 9,	8
641	COVID-19 and Pregnancy: Vertical Transmission and Inflammation Impact on Newborns. 2021, 9,	4
640	Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. 2021 , 184, 1821-183	5.eg/(6
639	Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor. 2021 , 12, 651403	6
638	Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates. 2021 ,	24

637	Vasculitis and Neutrophil Extracellular Traps in Lungs of Golden Syrian Hamsters With SARS-CoV-2. 2021 , 12, 640842	18
636	Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. 2021 , 66, 103291	9
635	Imaging infections in patients using pathogen-specific positron emission tomography. 2021, 13,	16
634	Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. 2021 , 12, 2295	48
633	Animal Models of COVID-19 II. Comparative Immunology. 2021 ,	9
632	A type I interferon response defines a conserved microglial state required for effective neuronal phagocytosis 2022 ,	1
631	Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors. 2021 , 58, 55-65	6
630	Low dose inocula of SARS-CoV-2 B.1.1.7 variant initiate more robust infections in the upper respiratory tract of hamsters than earlier D614G variants.	3
629	Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies. 2021 , 105, 307-311	5
628	Current Status of Putative Animal Sources of SARS-CoV-2 Infection in Humans: Wildlife, Domestic Animals and Pets. 2021 , 9,	18
627	Animal Models of COVID-19. I. Comparative Virology and Disease Pathogenesis. 2021,	12
626	mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. 2021 , 6, 57	60
625	COVID-19 and the human innate immune system. 2021 , 184, 1671-1692	175
624	Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. 2021 , 6, 61	29
623	The olfactory nerve is not a likely route to brain infection in COVID-19: a critical review of data from humans and animal models. 2021 , 141, 809-822	30
622	The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. 2021 , 12,	26
621	SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney.	0
620	SARS-CoV-2 bearing a mutation at the S1/S2 cleavage site exhibits attenuated virulence and confers protective immunity.	

619	Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden Syrian hamster model. 2021 ,	6
618	Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. 2021 , 19, 425-441	47
617	CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge. 2021 , 11, 8761	13
616	Vascular Inflammation Is Associated with Loss of Aquaporin 1 Expression on Endothelial Cells and Increased Fluid Leakage in SARS-CoV-2 Infected Golden Syrian Hamsters. 2021 , 13,	14
615	The Mechanisms and Animal Models of SARS-CoV-2 Infection. 2021 , 9, 578825	13
614	Cell-Type Apoptosis in Lung during SARS-CoV-2 Infection. 2021 , 10,	15
613	DNA vaccination induced protective immunity against SARS CoV-2 infection in hamsterss. 2021 , 15, e0009374	3
612	A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. 2021 , 5, 815-829	62
611	Spatially distributed infection increases viral load in a computational model of SARS-CoV-2 lung infection.	О
610	Comparative analyses of ACE2 and TMPRSS2 gene: Implications for the risk to which vertebrate animals are susceptible to SARS-CoV-2. 2021 , 93, 5487-5504	4
609	Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. 2021 , 7,	40
608	TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. 2021 , 184, 2618-2632.e17	26
607	Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. 2021 , 102,	2
606	Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant.	2
605	Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation. 2021 , 76, 2840-2854	23
604	SARS-CoV-2 infects human adult donor eyes and hESC-derived ocular epithelium. 2021 , 28, 1205-1220.e7	15
603	COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. 2021 , 13,	104
602	SARS-CoV-2 rapidly adapts in aged BALB/c mice and induces typical pneumonia. 2021 ,	15

601	An evaluation of 4 commercial assays for the detection of SARS-CoV-2 antibodies in a predominantly mildly symptomatic low prevalence Australian population. 2021 , 138, 104797	4
600	Male-Female Disparities in Years of Potential Life Lost Attributable to COVID-19 in the United States: A State-by-State Analysis. 2021 ,	O
599	[Susceptibility of animal species to experimental SARS-CoV-2 () infection]. 2021 , 66, 103-111	1
598	Topic: Hyper immune Bovine Colostrum as a Low-Cost, Large-Scale Source of Antibodies against COVID-19.	
597	Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice. 2021 , 67, 103381	40
596	Probenecid Inhibits SARS-CoV-2 Replication In Vivo and In Vitro.	
595	Repeated Exposure to Subinfectious Doses of SARS-CoV-2 May Promote T Cell Immunity and Protection against Severe COVID-19. 2021 , 13,	1
594	N-Glycolylneuraminic Acid in Animal Models for Human Influenza A Virus. 2021 , 13,	3
593	SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for spillback to New World rodents. 2021 , 17, e1009585	46
592	SARS-CoV-2-Morphology, Transmission and Diagnosis during Pandemic, Review with Element of Meta-Analysis. 2021 , 10,	4
591	Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient. 2021 ,	1
590	Possible effects of air temperature on COVID-19 disease severity and transmission rates. 2021 , 93, 5358-5366	4
589	Face masks effectively limit the probability of SARS-CoV-2 transmission. 2021 , 372,	73
588	Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe. 2021 ,	5
587	The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. 2021 , 96, 1262-1275	64
586	Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test.	1
585	On the road to ending the COVID-19 pandemic: Are we there yet?. 2021 , 557, 70-85	18
584	Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization. 2021 , 4, 597	13

583	Application of 3D bioprinting in the prevention and the therapy for human diseases. 2021 , 6, 177	11
582	Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19. 2021 , 13, e14150	27
581	No evidence of SARS-CoV-2 infection in Neotropical Primates sampled during COVID-19 pandemic in Minas Gerais and Rio Grande do Sul, Brazil.	
580	Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. 2021 , 68, 103403	50
579	Niclosamide inhalation powder made by thin-film freezing: Multi-dose tolerability and exposure in rats and pharmacokinetics in hamsters. 2021 , 603, 120701	5
578	Exposure route, sex, and age influence disease outcome in a golden Syrian hamster model of SARS-CoV-2 infection.	
577	SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. 2021 , 223, 2020-2028	16
576	Protective efficacy of rhesus adenovirus COVID-19 vaccines against mouse-adapted SARS-CoV-2. 2021 ,	1
575	Highly-Neutralizing COVID-19-Convalescent-Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.	2
574	The bat ACE2 and multiple animal orthologs are functional receptors for bat coronavirus RaTG13 and SARS-CoV-2. 2021 , 66, 1215-1227	9
573	SARS-CoV-2 B.1.1.7 Infection of Syrian Hamster Does Not Cause More Severe Disease, and Naturally Acquired Immunity Confers Protection. 2021 , e0050721	10
572	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. 2021 , 16, e0253487	31
571	Predictive Value of Precision-Cut Lung Slices for the Susceptibility of Three Animal Species for SARS-CoV-2 and Validation in a Refined Hamster Model. 2021 , 10,	4
570	Perilla (Perilla frutescens) leaf extract inhibits SARS-CoV-2 via direct virus inactivation. 2021 , 44, 293-303	5
569	Effect of prophylactic use of intra-nasal oil formulations in the hamster model of Covid-19.	
568	Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2. 2021 , 138, 111457	11
567	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. 2021 , 8, 684151	17
566	Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology.	1

565	Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. 2021 , 12, 3802		28
564	Animal models for SARS-CoV-2. 2021 , 48, 73-81		24
563	Visualization of SARS-CoV-2 infection dynamic.		3
562	Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report. 2021 , 8, ofab329		2
561	A Dual-Route Perspective of SARS-CoV-2 Infection: Lung- vs. Gut-specific Effects of ACE-2 Deficiency. 2021 , 12, 684610		5
560	SARS-CoV-2 Infects Hamster Testes. 2021 , 9,		7
559	Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate. 2021 , 95, e0223220		14
558	Polyphenols Sourced from Terrestrial and Marine Plants as Coronavirus Reproduction Inhibitors. 2021 , 66, 62-81		
557	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters. 2021 ,		4
556	Evaluation of efficacy of the amino acid-peptide complex administered intragastrically to golden hamsters experimentally infected with SARS-CoV-2. 2021 ,		
555	The SARS-CoV-2 mRNA vaccine breakthrough infection phenotype includes significant symptoms, live virus shedding, and viral genetic diversity. 2021 ,		12
554	Progression and Resolution of SARS-1 CoV-2 Infection in Golden Syrian Hamsters.		1
553	Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	25
552	The total number and mass of SARS-CoV-2 virions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	59
551	Characterization of a new SARS-CoV-2 variant that emerged in Brazil. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	25
550	Quantitative proteomics of hamster lung tissues infected with SARS-CoV-2 reveal host factors having implication in the disease pathogenesis and severity. 2021 , 35, e21713		3
549	Differential susceptibility of SARS-CoV-2 in animals: Evidence of ACE2 host receptor distribution in companion animals, livestock and wildlife by immunohistochemical characterisation. 2021 ,		7
548	Effectiveness of COVID-19 Convalescent Plasma Infusion Within 48 Hours of Hospitalization With SARS-CoV-2 Infection. 2021 , 13, e16746		

547	Cohabitation With a Known Coronavirus Disease 2019 Case Is Associated With Greater Antibody Concentration and Symptom Severity in a Community-Based Sample of Seropositive Adults. 2021 , 8, ofab244	1
546	Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2. 2021 ,	11
545	Animal Transmission of SARS-CoV-2 and the Welfare of Animals during the COVID-19 Pandemic. 2021 , 11,	3
544	Construction of a new chromosome-scale, long-read reference genome assembly of the Syrian hamster, Mesocricetus auratus.	1
543	Can Comorbidity Data Explain Cross-State and Cross-National Difference in COVID-19 Death Rates?. 2021 , 14, 2877-2885	1
542	Non-permissive SARS-CoV-2 infection in human neurospheres. 2021 , 54, 102436	6
541	A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens. 2021 , 24, 102699	4
540	COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes. 2021 , 61, 2295-2306	2
539	Cross-species higher sensitivities of FcRIIIA/FcRIV to afucosylated IgG for enhanced ADCC. 2021 , 4, 159-170	0
538	A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. 2021 , 36, 109400	35
537	A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19. 2021 , 6, 91	5
536	Sex and age bias viral burden and interferon responses during SARS-CoV-2 infection in ferrets. 2021 , 11, 14536	6
535	A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. 2021 , 13,	21
534	SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney. 2021 , 17, e1009705	16
533	Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters. 2021 ,	1
532	Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model. 2021 ,	3
531	PRE-CLINICAL IMMUNE RESPONSE AND SAFETY EVALUATION OF THE PROTEIN SUBUNIT VACCINE NANOCOVAX FOR COVID-19.	Ο
530	Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals. 2021 ,	4

529	Non-human primate models of human respiratory infections. 2021 , 135, 147-164	4
528	COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection. 2021 , 21, 710	31
527	Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks. 2021 , 9,	O
526	An Orally Available Cathepsin L Inhibitor Protects Lungs Against SARS-CoV-2-Induced Diffuse Alveolar Damage in African Green Monkeys.	1
525	Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters.	
524	Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. 2021 , 6, 97	41
523	Advances in micro-CT imaging of small animals. 2021 , 88, 175-192	10
522	Attenuated activation of pulmonary immune cells in mRNA-1273-vaccinated hamsters after SARS-CoV-2 infection. 2021 , 131,	4
521	SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity. 2021 , 12, e0141521	8
520	Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model. 2021 , 12, e0097421	22
519	Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters.	
518	Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection. 2021 , 12, e0159821	1
517	Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19. 2021 , 12, 4869	8
516	Viral and Bacterial Co-Infections in the Lungs: Dangerous Liaisons. 2021 , 13,	4
515	Male-Female Disparities in Years of Potential Life Lost Attributable to COVID-19 in the United States: A State-by-State Analysis. 2021 , 11, 7403	1
514	The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters. 2021 ,	5
513	Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. 2021 ,	3
512	I-lodo-DPA-713 Positron Emission Tomography in a Hamster Model of SARS-CoV-2 Infection. 2021 , 1	4

511	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. 2021 , 54, 2385-2398.e10	14
510	Impact of Prior Infection on Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Syrian Hamsters. 2021 , 12, 722178	3
509	Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19. 2021 , 17, e1009758	8
508	Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates. 2021 , 12, 626553	18
507	Longitudinal metabolomics of human plasma reveals prognostic markers of COVID-19 disease severity. 2021 , 2, 100369	14
506	History and prospects of intracytoplasmic sperm injection (ICSI) and the development of golden hamster ICSI embryos. 2021 , 20, 410-418	O
505	Infectious SARS-CoV-2 is emitted in aerosols.	O
504	Persisting lung pathogenesis and minimum residual virus in hamster after acute COVID-19. 2021 , 1	O
503	Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern. 2021 , 13, eabj3789	13
502	A thermostable oral SARS-CoV-2 vaccine induces mucosal and protective immunity.	1
501	Lack of efficacy of mono-mode of action therapeutics in COVID-19 therapy - How the lack of predictive power of preclinical cell and animal studies leads developments astray. 2021 ,	1
500	Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates. 2021 ,	2
499	A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. 2021 , 95, e0059221	4
498	Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters. 2021 , 12, 720437	1
497	Animal experiments show impact of vaccination on reduction of SARS-CoV-2 virus circulation: A model for vaccine development?. 2021 , 73, 1-7	4
496	Zoonotic and Reverse Zoonotic Transmissibility of SARS-CoV-2. 2021 , 302, 198473	7
495	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. 2021 , 13, eabj5413	18
494	Low dose inocula of SARS-CoV-2 Alpha variant transmits more efficiently than earlier variants in hamsters. 2021 , 4, 1102	8

493	Genetically diverse mouse models of SARS-CoV-2 infection reproduce clinical variation and cytokine responses in COVID-19 2022 ,	0
492	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. 2021 , 373, eabj0299	86
491	National Population-Level Disparities in COVID-19 Mortality Across the Intersection of Race/Ethnicity and Sex in the United States.	
490	Optimization of single dose VSV-based COVID-19 vaccination in hamsters. 2021 ,	1
489	SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. 2021 , 6, 337	34
488	ZRC3308 monoclonal antibody cocktail shows protective efficacy in Syrian hamsters against SARS-CoV-2 infection.	
487	A Model of a Novel Coronavirus Infection in Golden Syrian Hamsters: Major Pathological Changes. 2021 , 17, 90-94	0
486	The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. 2021 , 1, 15	1
485	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. 2021 , 95, e0097421	3
484	Cellular tropism of SARS-CoV-2 in the respiratory tract of Syrian hamsters and B6.Cg-Tg(K18-ACE2)2Prlmn/J transgenic mice. 2021 , 3009858211043084	1
483	Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro. 2021 , 11, 18085	4
482	Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants. 2021 , 95, e0068521	8
481	Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters. 2021 , 16, e0257191	7
480	Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	4
479	A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. 2021 , 12, 5469	23
478	Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity. 2021 , 21, e296-e301	29
477	Ad26.COV2.S Prevents SARS-CoV-2 Induced Pathways of Inflammation and Thrombosis in Hamsters.	
476	Ultra- and micro-structural changes of respiratory tracts in SARS-CoV-2 infected Syrian hamsters. 2021 , 52, 121	2

475	Coronaviruses, cholesterol and statins: Involvement and application for Covid-19. 2021 , 189, 51-64	5
474	Monitoring Group Activity of Hamsters and Mice as a Novel Tool to Evaluate COVID-19 Progression, Convalescence, and rVSV- G -Spike Vaccination Efficacy. 2021 , 9, 737627	Ο
473	Animal models of SARS-CoV-2 transmission. 2021 , 50, 8-16	11
472	Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test. 2021 , 13, 100313	4
471	In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters 2021 , 3, 100073	4
470	Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions. 2021 , 228, 107931	7
469	The peripheral T cell population is associated with pneumonia severity in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus 2.	
468	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence.	1
467	Experimental Animal Models of Coronavirus Infections: Strengths and Limitations. 2021, 21, e12	4
466	Male sex and age biases viral burden, viral shedding, and type 1 and 2 interferon responses during SARS-CoV-2 infection in ferrets. 2021 ,	3
465	Hamsters as a Model of Severe Acute Respiratory Syndrome Coronavirus-2. 2021 , 71, 398-410	1
464	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. 2021 , 6,	22
463	Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in hamsters.	1
462	SARS-CoV-2 therapeutics: how far do we stand from a remedy?. 2021 , 73, 750-768	6
461	Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting. 2021, 210, 65-72	35
460	Immunological and cardio-vascular pathologies associated with SARS-CoV-2 infection in golden syrian hamster.	6
459	Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. 2021 , 10, e1269	13
458	Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster. 2021 , 10, 797-809	15

457	ACTIVating Resources for the COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics. 2020 , 28, 646-659	22
456	A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. 2021 , 590, 320-325	74
455	SARS-CoV-2 Infection of Pluripotent Stem Cell-derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. 2020 ,	11
454	Convalescent Plasma for COVID-19. A randomized clinical trial.	83
453	Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection. 2020 ,	19
452	A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate.	11
451	SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months.	82
450	Prophylactic and Therapeutic Inhibition of In Vitro SARS-CoV-2 Replication by Oleandrin. 2020 ,	7
449	Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.	2
448	High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme.	4
447	The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis. 2021 ,	37
446	A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. 2020 ,	13
445	REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters.	15
444	Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. 2020 ,	6
443	SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents. 2020 ,	25
442	mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2. 2020 ,	6
441	Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice. 2020 ,	2
440	The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera.	14

439	SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model.	16
438	Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis. 2020 ,	71
437	Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins.	2
436	High efficacy of face masks explained by characteristic regimes of airborne SARS-CoV-2 virus abundance.	1
435	Non-permissive SARS-CoV-2 infection in human neurospheres. 2021 ,	2
434	High affinity modified ACE2 receptors protect from SARS-CoV-2 infection in hamsters.	10
433	Common genetic variation in humans impacts susceptibility to SARS-CoV-2 infection. 2020 ,	4
432	Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2.	3
431	A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters. 2020 ,	2
430	Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. 2020 ,	13
429	SARS-CoV-2 D614G Variant Exhibits Enhanced Replication and Earlier Transmission. 2020,	41
428	Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies.	3
427	Role of high-dose exposure in transmission hot zones as a driver of SARS-CoV2 dynamics. 2020 ,	2
426	Use of convalescent serum reduces severity of COVID-19 in nonhuman primates.	1
425	Decrease in Hospitalizations for COVID-19 after Mask Mandates in 1083 U.S. Counties.	4
424	mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents.	16
423	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.	18
422	SARS-CoV-2 spike D614G variant confers enhanced replication and transmissibility. 2020 ,	38

421	Nafamostat Mesylate in lipid carrier for nasal SARS-CoV2 titer reduction in a hamster model.	2
420	Longevity of seropositivity and neutralizing titers among SARS-CoV-2 infected individuals after 4 months from baseline: a population-based study in the province of Trento.	2
419	The total number and mass of SARS-CoV-2 virions. 2021 ,	5
418	Transmission of SARS-CoV-2 in domestic cats imposes a narrow bottleneck. 2021 ,	9
417	COVID-19-associated olfactory dysfunction reveals SARS-CoV-2 neuroinvasion and persistence in the olfactory system.	15
416	Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2.	2
415	Transmission and protection against re-infection in the ferret model with the SARS-CoV-2 USA-WA1/2020 reference isolate.	1
414	A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. 2020 ,	18
413	Impact of Convalescent Plasma Transfusion (CCP) In Patients With Previous Circulating Neutralizing Antibodies (nAb) to COVID-19.	1
412	Thiol drugs decrease SARS-CoV-2 lung injury and disrupt SARS-CoV-2 spike complex binding to ACE2. 2021 ,	11
411	Cell-type apoptosis in lung during SARS-CoV-2 infection. 2020 ,	8
410	Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. 2020 , 130, 6728-6738	106
409	Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity. 2020 , 130, 6204-6213	34
408	Antibody response to SARS-CoV-2 infection in humans: A systematic review. 2020 , 15, e0244126	130
407	mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2. 2020 , 16, e1009163	12
406	Making sense of rapid antigen testing in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics. 2020 ,	25
405	Anosmia: a missing link in the neuroimmunology of coronavirus disease 2019 (COVID-19). 2020 , 31, 691-701	41
404	Therapeutic MK-4482/EIDD-2801 Blocks SARS-CoV-2 Transmission in Ferrets. 2020 ,	7

403	SARS-CoV-2 Infected Cardiomyocytes Recruit Monocytes by Secreting CCL2. 2020 ,	4
402	Potential Medicinal Plants for the Treatment of Dengue Fever and Severe Acute Respiratory Syndrome-Coronavirus. 2020 , 11,	5
401	SARS, SARS again, and MERS. Review of animal models of human respiratory syndromes caused by coronavirus infections. 2020 , 97, 431-444	2
400	Establishment of a nonhuman primate model for development of vaccines and anti-viral drugs against COVID-19. 2021 ,	
399	COVID-19 Vaccines: Adenoviral Vectors. 2021 ,	1
398	Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission. 2021 , eabm3131	10
397	Infectious SARS-CoV-2 Is Emitted in Aerosol Particles. 2021 , 12, e0252721	11
396	De Novo Whole Genome Assembly of the Roborovski Dwarf Hamster (Phodopus roborovskii) Genome, an Animal Model for Severe/Critical COVID-19.	О
395	SARS-CoV-2 Infection Impacts Carbon Metabolism and Depends on Glutamine for Replication in Syrian Hamster Astrocytes.	2
394	Oral and intranasal Ad5 SARS-CoV-2 vaccines decrease disease and viral transmission in a golden hamster model.	3
393	Risk and Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Infection on Corneal Transplantation: A Case-Control Study 2022 , 41, 224-231	0
392	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. 2021 , 9, 1450-1466	31
391	Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis. 2021 ,	2
390	Effect of Prophylactic Use of Intranasal Oil Formulations in the Hamster Model of COVID-19. 2021 , 12, 746729	1
389	Abnormal Blood Coagulation and Kidney Damage in Aged Hamsters Infected with Severe Acute Respiratory Syndrome Coronavirus 2. 2021 , 13,	1
388	Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection. 2021 ,	2
387	SARS-CoV-2 causes lung infection without severe disease in human ACE2 knock-in mice. 2021 , JVI0151121	15
386	COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions. Proceedings of the National Academy of Sciences of the United States of America, 2021 , 118,	11

385	Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection. 2021 , 12, 5809	3
384	Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals. 2021 , 13,	12
383	Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease. 2021 , 24, 103219	4
382	Characterization of cells susceptible to SARS-COV-2 and methods for detection of neutralizing antibody by focus forming assay.	3
381	Antibody response to SARS-CoV-2 infection in humans: a systematic review.	5
3 80	Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques.	
379	Sequence analysis of Indian SARS-CoV-2 isolates shows a stronger interaction of mutated receptor binding domain with ACE2 receptor.	
378	Co-infection of SARS-CoV-2 and influenza virus causes more severe and prolonged pneumonia in hamsters. 2021 , 11, 21259	9
377	Immune interventions in COVID-19: a matter of time?. 2021 ,	2
376	Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient. 2021 ,	4
375	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. 2021 , 6, 129	8
374	Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants. 2021 , 39, 7001-7011	4
373	Reverse zoonosis of coronavirus disease-19: Present status and the control by one health approach 2021 , 14, 2817-2826	1
372	The Activin/FLRG pathway associates with poor COVID-19 outcomes in hospitalized patients. 2021 , MC	CB00467 <u>2</u> 1
371	Disruption of nasal bacteria enhances protective immune responses to influenza A virus and SARS-CoV-2 infection in mice.	
370	MTX-COVAB, a human-derived antibody with potent neutralizing activity against SARS-CoV-2 infection in vitro and in a hamster model of COVID-19.	O
369	COVID-19 AĪLARI; PANDEM D E SONA DO R U?.	O
368	Sterilizing immunity against SARS-CoV-2 in hamsters conferred by a novel recombinant subunit vaccine.	1

367	Natural Transmission and Experimental Models of SARS CoV-2 Infection in Animals. 2021, 71, 369-382	0
366	Oral vaccination protects against SARS-CoV-2 in a Syrian hamster challenge model. 2021 ,	4
365	Using animal models for studying SARS-CoV-2. 2021 , 1-17	2
364	COVID-19 Anosmia: High Prevalence, Plural Neuropathogenic Mechanisms, and Scarce Neurotropism of SARS-CoV-2?. 2021 , 13,	4
363	Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model. 2021 , 73, 103675	5
362	Syrian hamsters as a model of lung injury with SARS-CoV-2 infection: Pathologic, physiologic, and detailed molecular profiling. 2021 ,	3
361	An Update on Animal Models for Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Countermeasure Development. 2021 , 12, 770935	2
360	Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection. 2021 , 13,	O
359	Protective Effects of STI-2020 Antibody Delivered Post-Infection by the Intranasal or Intravenous Route in a Syrian Golden Hamster COVID-19 Model.	4
358	Risk mitigating behaviours in people with inflammatory joint and skin disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.	1
357	The Rhinolophus affinis bat ACE2 and multiple animal orthologs are functional receptors for bat coronavirus RaTG13 and SARS-CoV-2.	
356	Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro.	
355	Effect of hot zone infection outbreaks on the dynamics of SARS-CoV-2 spread in the community at large.	
354	Tiermodelle zur Erforschung von SARS-CoV-2 und COVID-19. 2020 , 4, 166-173	
353	An overview of preclinical animal models for SARS-CoV-2 pathogenicity. 2021 , 153, 17-25	1
352	Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. 2021 , 12, 772240	7
351	Infection and transmission of ancestral SARS-CoV-2 and its alpha variant in pregnant white-tailed deer. 2021 , 1-39	18
350	Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. 2021 , 103379	2

349	No Evidence of SARS-CoV-2 Infection in Neotropical Primates Sampled During COVID-19 Pandemic in Minas Gerais and Rio Grande do Sul, Brazil. 2021 , 1	2
348	Animal models for SARS-CoV-2 infection and pathology 2021 , 2, 548	10
347	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. 2021 , JVI0155121	8
346	Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19. 2021 ,	2
345	Neurological complications and infection mechanism of SARS-COV-2. 2021 , 6, 406	16
344	ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury. 2021 , 12, 6791	9
343	Ecology, evolution and spillover of coronaviruses from bats. 2021 ,	14
342	Golden Syrian Hamsters as a Model for Revisiting the Role of Biological Sex Differences in SARS-CoV-2 Infection. 2021 , e0184821	O
341	Understanding COVID-19: From Dysregulated Immunity to Vaccination Status Quo. 2021 , 12, 765349	3
340	Susceptibility of sheep to experimental co-infection with the ancestral lineage of SARS-CoV-2 and its alpha variant. 2021 ,	Ο
339	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. 2021 , 11, 22848	8
338	Progression and Resolution of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Golden Syrian Hamsters. 2021 ,	6
337	Host parameters and mode of infection influence outcome in SARS-CoV-2-infected hamsters. 2021 , 24, 103530	4
336	Hamster models of COVID-19 pneumonia reviewed: How human can they be?. 2021 , 3009858211057197	9
335	Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies. 2021 , 7, e08444	0
334	Replacement Strategies for Animal Studies in Inhalation Testing. 2021 , 3, 45	O
333	An overview of preclinical animal models for SARS-CoV-2 pathogenicity. 2021 , 153, 17	1
332	Fundamentals of genomic epidemiology, lessons learned from the coronavirus disease 2019 (COVID-19) pandemic, and new directions. 2021 , 1,	2

331	A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models 2022 ,	5
330	Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters 2021 , 12, 788235	3
329	Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters.	19
328	I. Animal Models of SARS-CoV-2 Infection and Pathogenesis. 2020 , 109, 2260-2263	1
327	BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2 2022 , 24, 24-34	5
326	[Specific features of the pathology of the respiratory system in SARS-CoV-2 (Coronaviridae: Coronavirinae: Betacoronavirus: Sarbecovirus) infected Syrian hamsters (Mesocricetus auratus)] 2022 , 66, 442-451	
325	Pathogenicity of SARS-CoV-2 Omicron in Syrian hamsters and its neutralization with different Variants of Concern.	0
324	SARS-CoV-2 Reverse Zoonoses to Pumas and Lions, South Africa 2022 , 14,	5
323	Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2 2022 , e0290621	3
322	Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants 2022,	1
321	Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues.	0
320	Research-Relevant Conditions and Pathology of Laboratory Mice, Rats, Gerbils, Guinea Pigs, Hamsters, Naked Mole Rats, and Rabbits 2022 ,	3
319	Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection 2022 , 11,	0
318	SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters 2022,	89
317	Mucociliary Transport Deficiency and Disease Progression in Syrian Hamsters with SARS-CoV-2 Infection 2022 ,	Ο
316	Recovery of anosmia in hamsters infected with SARS-CoV-2 is correlated with repair of the olfactory epithelium 2022 , 12, 628	5
315	Comprehensive analysis of disease pathology in immunocompetent and immunocompromised hamster models of SARS-CoV-2 infection.	1
314	Age-dependent pathogenic characteristics of SARS-CoV-2 infection in ferrets 2022 , 13, 21	6

313	SARS-CoV-2 infection results in lasting and systemic perturbations post recovery.	3
312	Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model 2022 , 110394	2
311	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants 2021 , 8, 836826	0
310	SARS-CoV-2 infection triggers paracrine senescence and leads to a sustained senescence-associated inflammatory response.	1
309	Bacteriophage-derived dsRNA exerts anti-SARS-CoV-2 activity in vitro and in Golden Syrian hamsters in vivo.	
308	Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein 2021 , 40, 574-574	O
307	Advances and gaps in SARS-CoV-2 infection models 2022, 18, e1010161	13
306	In-vitro and In-vivo Experimental Models for MERS-CoV, SARS-CoV and SARS-CoV-2 Viral Infection: A Compendious Review 2022 ,	
305	Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates 2022 , 7, 7	7
304	Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication 2022 , 14,	3
303	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies 2022 ,	102
302	Non-cell-autonomous disruption of nuclear architecture as a potential cause of COVID-19-induced anosmia 2022 ,	19
301	SARS-CoV-2 Infection and Lung Regeneration 2022 , e0018821	4
300	Susceptibility of sheep to experimental co-infection with the ancestral lineage of SARS-CoV-2 and its alpha variant 2022 , 1-27	4
299	Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model 2022 , e0304421	1
298	The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters 2022 ,	O
297	Disulfiram inhibits neutrophil extracellular trap formation protecting rodents from acute lung injury and SARS-CoV-2 infection 2022 ,	4
296	The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters 2022 , 18, e1009914	3

295	Characterization of Two Heterogeneous Lethal Mouse-Adapted SARS-CoV-2 Variants Recapitulating Representative Aspects of Human COVID-19 2022 , 13, 821664	5
294	A highly attenuated SARS-CoV-2 related pangolin coronavirus variant has a 104nt deletion at the 3?-terminus untranslated region.	Ο
293	Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice 2022 ,	6
292	Modeling SARS-CoV-2: Comparative Pathology in Rhesus Macaque and Golden Syrian Hamster Models 2022 , 1926233211072767	3
291	Mitochondrial DNA Diversity of Mesocricetus auratus and Other Cricetinae Species among Cricetidae Family 2022 , 1	O
290	Metalloproteinase-dependent and TMPRSS2-independnt cell surface entry pathway of SARS-CoV-2 requires the furin-cleavage site and the S2 domain of spike protein.	1
289	Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19 2021 , 12, 766112	5
288	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift 2021 ,	204
287	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift 2021,	16
286	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies.	10
285	Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from disease caused by the Omicron variant.	2
284	Can a combination of vaccination and face mask wearing contain the COVID-19 pandemic?. 2021,	8
283	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies 2021 ,	22
282	The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters 2021 ,	17
281	[Engineered ACE2 receptor has a potential for a new therapy of COVID-19] 2022, 157, 155	
280	Next-generation intranasal Covid-19 vaccine: a polymersome-based protein subunit formulation that provides robust protection against multiple variants of concern and early reduction in viral load of the upper airway in the golden Syrian hamster model.	O
279	A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection 2022 , 13, 811430	1
278	Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant 2022 , 13, 845316	O

277	Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19.	3
276	A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity 2022 , 13, 837443	3
275	Impaired detection of omicron by SARS-CoV-2 rapid antigen tests 2022 , 1	9
274	Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model 2022 ,	O
273	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2 2022,	3
272	Dynamic Changes of the Blood Chemistry in Syrian Hamsters Post-Acute COVID-19 2022 , 10, e0236221	O
271	Fatal Neurodissemination and SARS-CoV-2 Tropism in K18-hACE2 Mice Is Only Partially Dependent on hACE2 Expression 2022 , 14,	7
270	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice 2022 ,	3
269	Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice 2022, 12, 4150	0
268	Immune durability and protection against SARS-CoV-2 re-infection in Syrian hamsters 2022 , 1-29	O
267	Intranasal Immunization with a Proteosome-Adjuvanted SARS-CoV2 Spike Protein-Based Vaccine is Immunogenic and Efficacious in Mice & Tamsters.	О
266	Defining the risk of SARS-CoV-2 variants on immune protection 2022 ,	7
265	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults 2022,	23
264	Timing of exposure is critical in a highly sensitive model of SARS-CoV-2 transmission 2022 , 18, e1010181	1
263	MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters 2022 , 13, 845969	2
262	Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?. 2022 , 1, 2-27	2
261	Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters 2022 , 110688	1
260	Mechanisms of olfactory dysfunction due to COVID-19. 2022 , 53, 141-146	

259	Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns 2022 , 18, e1010340	2
258	Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy 2022 ,	1
257	BCG vaccination provides protection against IAV but not SARS-CoV-2 2022, 110502	4
256	Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19 2022 , 14, 2047144	1
255	Structure-based dual affinity optimization of a SARS-CoV-1/2 cross-reactive single-domain antibody 2022 , 17, e0266250	О
254	Comparative infection and pathogenesis of SARS-CoV-2 Omicron and Delta variants in aged and young Syrian hamsters.	1
253	Thinking Outside the Box: Utilizing Nontraditional Animal Models for COVID-19 Research. 2022 , 2, 113-133	1
252	Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models 2022 , 60, 255-267	3
251	Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge 2022 , 7, 36	3
250	SARS-CoV-2 pathogenesis 2022 ,	30
250 249	SARS-CoV-2 pathogenesis 2022, The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication and Decreases Viral Titers and Disease Progression in Syrian Hamsters 2022, e0370521	30
	The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication	
249	The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication and Decreases Viral Titers and Disease Progression in Syrian Hamsters 2022 , e0370521 Review of selected animal models for respiratory coronavirus infection and its application in drug	1
249	The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication and Decreases Viral Titers and Disease Progression in Syrian Hamsters 2022, e0370521 Review of selected animal models for respiratory coronavirus infection and its application in drug research 2022, SARS-CoV-2 Omicron spike H655Y mutation is responsible for enhancement of the endosomal	1
249 248 247	The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication and Decreases Viral Titers and Disease Progression in Syrian Hamsters 2022, e0370521 Review of selected animal models for respiratory coronavirus infection and its application in drug research 2022, SARS-CoV-2 Omicron spike H655Y mutation is responsible for enhancement of the endosomal entry pathway and reduction of cell surface entry pathways. Immunization with recombinant accessory protein-deficient SARS-CoV-2 protects against lethal	1
249 248 247 246	The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication and Decreases Viral Titers and Disease Progression in Syrian Hamsters 2022, e0370521 Review of selected animal models for respiratory coronavirus infection and its application in drug research 2022, SARS-CoV-2 Omicron spike H655Y mutation is responsible for enhancement of the endosomal entry pathway and reduction of cell surface entry pathways. Immunization with recombinant accessory protein-deficient SARS-CoV-2 protects against lethal challenge and viral transmission 2022, Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory	1 0 5
249 248 247 246 245	The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication and Decreases Viral Titers and Disease Progression in Syrian Hamsters 2022, e0370521 Review of selected animal models for respiratory coronavirus infection and its application in drug research 2022, SARS-CoV-2 Omicron spike H655Y mutation is responsible for enhancement of the endosomal entry pathway and reduction of cell surface entry pathways. Immunization with recombinant accessory protein-deficient SARS-CoV-2 protects against lethal challenge and viral transmission 2022, Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model.	1 0 5

241	Parsing the role of NSP1 in SARS-CoV-2 infection 2022 ,	0
240	Antiviral roles of interferon regulatory factor (IRF)-1, 3 and 7 against human coronavirus infection.	
239	Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2.	0
238	Animal models in SARS-CoV-2 research 2022 ,	2
237	SARS-CoV-2 Infection Induces Ferroptosis of Sinoatrial Node Pacemaker Cells 2022 , CIRCRESAHA121320518	1
236	Lithium salts as a treatment for COVID-19: Pre-clinical outcomes 2022 , 149, 112872	О
235	Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern 2022 , 79, 103997	1
234	ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection 2021 , 13,	1
233	Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. 2021 , 39-68	
232	Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters 2022 , 14, 2018900	7
231	Persimmon-derived tannin has antiviral effects and reduces the severity of infection and transmission of SARS-CoV-2 in a Syrian hamster model. 2021 , 11, 23695	3
230	Use of Micro-Computed Tomography to Visualize and Quantify COVID-19 Vaccine Efficiency in Free-Breathing Hamsters 2022 , 2410, 177-192	1
229	Propagation of SARS-CoV-2 in Calu-3 Cells to Eliminate Mutations in the Furin Cleavage Site of Spike 2021 , 13,	1
228	Considerations for the Safe Operation of Schools During the Coronavirus Pandemic 2021 , 9, 751451	1
227	Activity of Galidesivir in a Hamster Model of SARS-CoV-2 2021 , 14,	0
226	QTQTN motif upstream of the furin-cleavage site plays key role in SARS-CoV-2 infection and pathogenesis.	О
225	Conjunctival epithelial cells resist productive SARS-CoV-2 infection.	
224	Combinatorial mRNA vaccination enhances protection against SARS-CoV-2 delta variant.	1

223 Timing of exposure is critical in a highly sensitive model of SARS-CoV-2 transmission.

222	Spatially distributed infection increases viral load in a computational model of SARS-CoV-2 lung infection 2021 , 17, e1009735	o
221	SARS-CoV-2 Interference of Influenza Virus Replication in Syrian Hamsters. 2021 ,	4
220	Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens. 2021 , 17, e1010085	2
219	A humanized mouse model of chronic COVID-19 2021 ,	8
218	Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual.	O
217	COVID-19 mRNA Vaccines Preserve Immunogenicity after Re-Freezing 2022, 10,	O
216	Evolution of nasal and olfactory infection characteristics of SARS-CoV-2 variants 2022,	1
215	Ocular tropism of SARS-CoV-2 with retinal inflammation through neuronal invasion in animal models.	
214	Ad26.COV2.S prevents upregulation of SARS-CoV-2 induced pathways of inflammation and thrombosis in hamsters and rhesus macaques 2022 , 18, e1009990	O
213	Preclinical efficacy and safety of novel SNAT against SARS-CoV-2 using a hamster model 2022, 1	O
212	Broadly neutralizing antibodies target the coronavirus fusion peptide 2022,	3
211	Preclinical study of a DNA vaccine targeting SARS-CoV-2 2022 , 70, 103348	0
210	Covax-19/Spikogen vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters 2022 ,	О
209	Detection of SARS-CoV-2 peptide-specific antibodies in Syrian hamster serum by ELISA 2022 , 113275	
208	A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2 2022 , 7, 47	1
207	is a null mutation of Cryptochrome 1 in Syrian hamsters <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2123560119	11.5 1
206	SARS-CoV-2 Virus-like Particles Produced by a Single Recombinant Baculovirus Generate Anti-S Antibody and Protect against Variant Challenge. 2022 , 14, 914	1

205	Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters 2022 , 7, 49	О
204	SARS-CoV-2 Droplet and Airborne Transmission Heterogeneity 2022 , 11,	2
203	Reduced SARS-CoV-2 disease outcomes in Syrian hamsters receiving immune sera: Quantitative image analysis in pathologic assessments 2022 , 3009858221095794	O
202	Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model 2022 , eabn6868	6
201	Spatiotemporal landscape of SARS-CoV-2 pulmonary infection reveals Slamf9+Spp1+ macrophages promoting viral clearance and inflammation resolution.	1
200	SARS-CoV-2-related pangolin coronavirus exhibits similar infection characteristics to SARS-CoV-2 and direct contact transmissibility in hamsters 2022 , 104350	1
199	Inhibitors of dihydroorotate dehydrogenase cooperate with Molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication 2022 , 104293	0
198	The Reassessed Potential of SARS-CoV-2 Attenuation for COVID-19 Vaccine Development Systematic Review. 2022 , 14, 991	2
197	COVID-19 vaccine development: milestones, lessons and prospects 2022 , 7, 146	13
196	Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice. 2022 , 13,	3
195	Activity of a Carbohydrate-Binding Module Therapy, Neumifil, against SARS-CoV-2 Disease in a Hamster Model of Infection. 2022 , 14, 976	1
194	Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model 2022,	2
193	Mechanistic Models of COVID-19: Insights into Disease Progression, Vaccines, and Therapeutics 2022 , 106606	O
192	Characterization of the SARS-CoV-2 B.1.621 (Mu) variant 2022 , eabm4908	1
191	Are Hamsters a Suitable Model for Evaluating the Immunogenicity of RBD-Based Anti-COVID-19 Subunit Vaccines?. 2022 , 14, 1060	2
190	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2 2022,	8
189	Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice 2022 , 18, e1010498	1
188	How time-scale differences in asymptomatic and symptomatic transmission shape SARS-CoV-2 outbreak dynamics.	O

187	Acute Vaping of a golden Syrian Hamster is Feasible and Leads to Nicotine-Dependent Respiratory Tract Inflammation.	
186	A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. 2022 ,	2
185	Animal models for studying coronavirus infections and developing antiviral agents and vaccines. 2022 , 203, 105345	1
184	Immune Responses of a Novel Bi-Cistronic SARS-CoV-2 DNA Vaccine Following Intradermal Immunization With Suction Delivery. 2,	O
183	COH04S1 and Beta Sequence Modified Vaccine Protect Hamsters From SARS-CoV-2 Variants. 2022 , 104457	О
182	Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.	2
181	Non-Productive Infection of Glial Cells with SARS-CoV-2 in Hamster Organotypic Cerebellar Slice Cultures. 2022 , 14, 1218	
180	SARS-CoV-2 and influenza A virus co-infection alters viral tropism and hematological composition in Syrian hamsters.	1
179	A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection. 2022 , 7,	2
178	A dimeric proteomimetic prevents SARS-CoV-2 infection by dimerizing the spike protein.	O
177	Mouse models in COVID-19 research: analyzing the adaptive immune response.	1
176	Novel application of [18F]DPA714 for visualizing the pulmonary inflammation process of SARS-CoV-2-infection in rhesus monkeys (Macaca mulatta). 2022 , 112-113, 1-8	
175	Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy. 2022 , 29,	
174	Protective efficacy of COVAXIN against Delta and Omicron variants in hamster model.	
173	Oral SARS-CoV-2 Inoculation Causes Nasal Viral Infection Leading to Olfactory Bulb Infection: An Experimental Study. 12,	2
172	Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans. 13,	O
171	Antiviral efficacy of selective estrogen receptor modulators against SARS-CoV-2 infection in vitro and in vivo reveals bazedoxifene acetate as an entry inhibitor.	
170	Conjunctival epithelial cells resist productive SARS-CoV-2 infection. 2022 ,	O

169	SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters. 2022 , 13,	5
168	Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis. 2022 , 18, e1010627	6
167	Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters. 2022 , 12,	0
166	Potent human broadly SARS-CoV-2fleutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. 2022 , 219,	3
165	Intranasal vaccination of hamsters with a Newcastle disease virus vector expressing the S1 subunit protects animals against SARS-CoV-2 disease. 2022 , 12,	0
164	Fc-modified SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models.	
163	A diminished immune response underlies age-related SARS-CoV-2 pathologies. 2022 , 111002	0
162	Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.	3
161	Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein.	2
160	Severe Acute Respiratory Syndrome Coronavirus 2 Nosode: A Potential Alternative Vaccine Platform. 2022 , 23, 133-134	
159	SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations post recovery.	9
158	Hyper-Immune Bovine Milk as an Immunological and Nutritional Supplement for COVID-19. 9,	O
157	Comprehensive Analysis of Disease Pathology in Immunocompetent and Immunocompromised Hosts following Pulmonary SARS-CoV-2 Infection. 2022 , 10, 1343	0
156	Investigating SARS-CoV-2 Susceptibility in Animal Species: A Scoping Review. 2022 , 16, 117863022211077	1
155	Experimental Models of SARS-COV-2 Infection in the Central Nervous System. 2022 , 14, 117957352211022	
154	The nervous system during COVID -19: Caught in the crossfire *.	1
153	Cardiopulmonary Injury in the Syrian Hamster Model of COVID-19. 2022 , 14, 1403	1
152	Masks Do No More Than Prevent Transmission: Theory and Data Undermine the Variolation Hypothesis.	O

151	Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19.	1
150	Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2. 2022 , 7,	2
149	Cell and Animal Models for SARS-CoV-2 Research. 2022 , 14, 1507	3
148	Pathobiology and dysbiosis of the respiratory and intestinal microbiota in 14 months old Golden Syrian hamsters infected with SARS-CoV-2.	
147	Animal models for COVID-19: advances, gaps and perspectives. 2022 , 7,	4
146	De Novo-Whole Genome Assembly of the Roborovski Dwarf Hamster (Phodopus roborovskii) Genome: An Animal Model for Severe/Critical COVID-19. 2022 , 14,	O
145	Omicron BA.1 and BA.2 sub-lineages show reduced pathogenicity and transmission potential than the early SARS-CoV-2 D614G variant in Syrian hamsters.	1
144	Alteration of the gut microbiotal composition and metabolic output correlates with COVID-19-like severity in obese NASH hamsters. 2022 , 14,	1
143	Decrease in Angiotensin Converting Enzyme 2 activity but not concentration in plasma/lungs in COVID-19 patients Ibffers clues for diagnosis/treatment. 2022 ,	О
142	Broadly neutralizing antibodies target the coronavirus fusion peptide.	7
141	Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. 2022 , 6, 791-805	3
140	The Host Response to Influenza A Virus Interferes with SARS-CoV-2 Replication during Coinfection.	2
139	SARS-CoV -2 Infection Impacts Carbon Metabolism and Depends on Glutamine for Replication in Syrian Hamster Astrocytes.	1
138	QTQTN motif upstream of the furin-cleavage site plays a key role in SARS-CoV-2 infection and pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119,	11.5 3
137	Combined Diagnosis of SARS-CoV-2: Rapid Antigen Detection as an Adjunct to Nucleic Acid Detection.	
136	BSL2-compliant lethal mouse model of SARS-CoV-2 and variants of concern to evaluate therapeutics targeting the Spike protein. 13,	
135	Development of transgenic models susceptible and resistant to SARS-CoV-2 infection in FVB background mice. 2022 , 17, e0272019	О
134	Matrix Metalloproteinases Expression Is Associated with SARS-CoV-2-Induced Lung Pathology and Extracellular-Matrix Remodeling in K18-hACE2 Mice. 2022 , 14, 1627	O

133	SARS-CoV-2 ORF8 is a viral cytokine regulating immune responses.	O
132	SARS-CoV-2 Airway Infection Results in Time-dependent Sensory Abnormalities in a Hamster Model.	O
131	Recombinant Human ACE2-Fc : A promising therapy for SARS-CoV2 infection.	
130	Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates.	1
129	Bacteriophage-Derived Double-Stranded RNA Exerts Anti-SARS-CoV-2 Activity In Vitro and in Golden Syrian Hamsters In Vivo. 2022 , 15, 1053	
128	Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19.	O
127	Understanding COVID-19-associated coagulopathy.	10
126	DOCK2 is involved in the host genetics and biology of severe COVID-19.	1
125	COVID-19: A Veterinary and One Health Perspective.	0
124	TEMPOL inhibits SARS-CoV-2 replication and development of lung disease in the Syrian hamster model. 2022 , 25, 105074	O
123	Tempol Inhibits SARS-CoV-2 Replication and Development of Lung Disease in the Syrian Hamster Model.	O
122	Approach for the study of COVID-19 infection and vaccine development using mice model: A narrative review. 2022 ,	O
121	Covid-Associated Pernio is the Product of an Abortive Sars-Cov-2 Infection Resulting in the Deposition of Inflammatory Viral Rna and a Local Interferon Response.	0
120	Impact of reinfection with SARS-CoV-2 Omicron variants in previously infected hamsters.	O
119	SARS-CoV-2 does not infect pigs, but this has to be verified regularly. 2022 , 29,	O
118	Neuroinvasion and anosmia are independent phenomena upon infection with SARS-CoV-2 and its variants.	O
117	Acute vaping of a golden Syrian hamster causes inflammatory response transcriptomic changes.	1
116	After the virus has cleared©an preclinical models be employed for Long COVID research?. 2022 , 18, e1010741	1

115	SARS-CoV-2 ORF8 is a viral cytokine regulating immune responses.	O
114	Diet-Induced Obesity and NASH Impair Disease Recovery in SARS-CoV-2-Infected Golden Hamsters. 2022 , 14, 2067	1
113	Use of the particle agglutination/particle agglutination-inhibition test for antigenic analysis of SARS-CoV-2.	0
112	Protection against SARS-CoV-2 transmission by a parenteral primeIntranasal boost vaccine strategy. 2022 , 104248	1
111	Delayed SARS-CoV-2 Spread and Olfactory Cell Lineage Impairment in Close-Contact Infection Syrian Hamster Models.	O
110	SARS-CoV-2 Uses Nonstructural Protein 16 to Evade Restriction by IFIT1 and IFIT3.	O
109	Preventing spread of aerosolized infectious particles during medical procedures: A lab-based analysis of an inexpensive plastic enclosure. 2022 , 17, e0273194	O
108	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2.	1
107	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant.	2
106	Increased pathogenicity and aerosol transmission for one SARS-CoV-2 B.1.617.2 Delta variant over the wild-type strain in hamsters. 2022 ,	O
105	Trust in COVID -19 public health information.	O
104	Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. 2022 , 14,	5
103	Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model. 2022 , 18, e1010807	O
102	Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants. 2022 , 111528	O
101	Gut as an Alternative Entry Route for SARS-CoV-2: Current Evidence and Uncertainties of Productive Enteric Infection in COVID-19. 2022 , 11, 5691	1
100	Prophylactic Effect of Ivermectin on SARS-CoV-2 Induced Disease in a Syrian Hamster Model.	O
99	No Evidence for the Presence of SARS-CoV-2 in Bank Voles and Other Rodents in Germany, 2020\(\textbf{Q} 022. \) 2022, 11, 1112	О
98	In vitro and in vivo differences in neurovirulence between D614G, Delta And Omicron BA.1 SARS-CoV-2 variants. 2022 , 10,	4

97	Protective efficacy of COVAXINI against Delta and Omicron variants in hamster model. 2022 , 25, 105178	O
96	A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8.	O
95	IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern. 2022 , 13,	0
94	SARS CoV-2 infections in animals, two years into the pandemic.	1
93	Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment. 2022 , 16, 17534666221132	270
92	SARS-CoV-2 from COVID-19 Patients in the Republic of Moldova: Whole-Genome Sequencing Results. 2022 , 14, 2310	O
91	Comparison of the pathogenesis of SARS-CoV-2 infection in K18-hACE2 mice and Syrian golden hamster models.	2
90	Nebulized mRNA-Encoded Antibodies Protect Hamsters from SARS-CoV-2 Infection. 2202771	O
89	Pathobiology and dysbiosis of the respiratory and intestinal microbiota in 14 months old Golden Syrian hamsters infected with SARS-CoV-2. 2022 , 18, e1010734	O
88	Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection. 2022 , 12,	O
87	The pathophysiological and immunological background of the monkeypox virus infection: An update.	2
86	Characteristics of animal models for COVID-19. 2022 , 5, 401-409	2
85	Evidence for the spread of SARS-CoV-2 and olfactory cell lineage impairment in close-contact infection Syrian hamster models. 12,	0
84	Intranasal virus-particle mimicking vaccine enhances SARS-CoV-2 clearance in the Syrian hamster model.	O
83	Anti-SARS-CoV-2 Activity of Adamantanes In Vitro and in Animal Models of Infection. 2022, 2, 1551-1563	O
82	Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice. 2022 , 17, e0272594	O
81	Intranasal delivery of a chimpanzee adenovirus vector expressing a pre-fusion spike (BV-AdCoV-1) protects golden Syrian hamsters against SARS-CoV-2 infection. 12,	О
80	Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents.	1

79	S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.	3
78	Immunoglobulin Y Specific for SARS-CoV-2 Spike Protein Subunits Effectively Neutralizes SARS-CoV-2 Infectivity and Ameliorates Disease Manifestations In Vivo. 2022 , 10, 2774	Ο
77	Versatile live-attenuated SARS-CoV-2 vaccine platform applicable to variants induces protective immunity. 2022 , 25, 105412	1
76	Intrinsic host susceptibility among multiple species to intranasal SARS-CoV-2 identifies diverse virological, biodistribution and pathological outcomes. 2022 , 12,	O
75	Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters. 2022 , 13,	1
74	A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein.	2
73	Comparative study of the pathogenicity of SARS-CoV-2 B.1 AND B.1.617.2 lineages for syrian hamsters. 2022 , 2, 125-136	О
72	Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models 2022 , 105596	O
71	Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses. 2022 , 86, 104341	1
70	Household Transmission of SARS-CoV-2 from Humans to Pets, Washington and Idaho, USA. 2022 , 28,	1
69	Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster. 2022 , 10, 1996	О
68	Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice. 2022 , 14, 2584	O
67	In-depth characterization of the Syrian hamster as translational model for COVID-19 in humans.	О
66	Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice. 2022 , 2,	1
65	Comparative study of Wuhan-like and omicron-like variants of SARS-CoV-2 in experimental animal models. 2022 , 67, 439-449	О
64	An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission.	O
63	Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters.	О
62	COVID-19 instigates adipose browning and atrophy through VEGF in small mammals. 2022 , 4, 1674-1683	О

61	Omicron-specific mRNA vaccine induced cross-protective immunity against ancestral SARS-CoV-2 infection with low neutralizing antibodies. 2023 , 95,	0
60	Detection of Airborne Influenza A and SARS-CoV-2 Virus Shedding following Ocular Inoculation of Ferrets. 2022 , 96,	O
59	Methotrexate inhibition of SARS-CoV-2 entry, infection and inflammation revealed by bioinformatics approach and a hamster model. 13,	0
58	Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo. 2022 , 8,	O
57	Induction of significant neutralizing antibodies against SARS-CoV-2 by a highly attenuated pangolin coronavirus variant with a 104nt deletion at the 3'-UTR. 2023 , 12,	0
56	CLEC5A expression can be triggered by spike glycoprotein and may be a potential target for COVID-19 therapy.	О
55	Ocular tropism of SARS-CoV-2 in animal models with retinal inflammation via neuronal invasion following intranasal inoculation. 2022 , 13,	2
54	Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19.	О
53	A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & amp; 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration. 2022 , 8,	O
52	Susceptibility of SARS Coronavirus-2 infection in domestic and wild animals: a systematic review. 2023 , 13,	1
51	Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19. 2022 , 13,	O
50	Mucociliary transport deficiency and disease progression in Syrian hamsters with SARS-CoV-2 infection. 2023 , 8,	О
49	Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.	O
48	Microvascular significance of TGF-laxis activation in COVID-19. 9,	1
47	Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. 2023 , 15, 175	5
46	Pathogenesis of Breakthrough Infections with SARS-CoV-2 Variants in Syrian Hamsters.	О
45	Pharmacological Activities of Fingerroot Extract and Its Phytoconstituents Against SARS-CoV-2 Infection in Golden Syrian Hamsters. Volume 15, 13-26	0
44	Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection.	О

43	Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea. 2023 , 102189	Ο
42	Do SARS-CoV-2 Variants Differ in Their Neuropathogenicity?.	O
41	Human Adenovirus and Influenza A Virus Exacerbate SARS-CoV-2 Infection in Animal Models. 2023 , 11, 180	O
40	Effects of yogurt containing probiotics on respiratory virus infections: Influenza H1N1 and SARS-CoV-2. 2023 ,	1
39	Innate immune evasion strategies of SARS-CoV-2.	1
38	An inactivated SARS-CoV-2 vaccine induced cross-neutralising persisting antibodies and protected upon challenge in small animals. 2023 , 105949	O
37	How time-scale differences in asymptomatic and symptomatic transmission shape SARS-CoV-2 outbreak dynamics. 2023 , 100664	1
36	Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19. 2022 , 22, 414-434	Ο
35	Severe Acute Respiratory Syndrome Coronavirus-2 Delta Variant Study In Vitro and Vivo. 2023 , 45, 249-267	Ο
34	Generation and Characterization of a SARS-CoV-2-Susceptible Mouse Model Using Adeno-Associated Virus (AAV6.2FF)-Mediated Respiratory Delivery of the Human ACE2 Gene. 2023 , 15, 85	1
33	HIF-1Dependent Metabolic Reprogramming, Oxidative Stress, and Bioenergetic Dysfunction in SARS-CoV-2-Infected Hamsters. 2023 , 24, 558	1
32	Animal models of COVID-19 and complications. 2023 , 623-636	Ο
31	Editing the Genome of the Golden Hamster (Mesocricetus auratus). 2023, 247-254	O
30	T cell immunity ameliorates COVID-19 disease severity and provides post-exposure prophylaxis after peptide-vaccination, in Syrian hamsters. 14,	O
29	SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses. 14,	0
28	Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals.	O
27	A role for Toll-like receptor 3 in lung vascular remodeling associated with SARS-CoV-2 infection.	О
26	SARS-CoV-2 infection induces persistent adipose tissue damage in aged golden Syrian hamsters. 2023 , 14,	Ο

25	EXPERIMENTAL MODEL OF SARS COV-2 IN YOUNG SYRIAN HAMSTERS FOR PRECLINICAL STUDIES. 2022 ,	O
24	Vaccines. 2023 , 335-396	O
23	Convalescent human IgG, but not IgM, from COVID-19 survivors confers dose-dependent protection against SARS-CoV-2 replication and disease in hamsters. 14,	0
22	Genome-scale CRISPR-Cas9 screen identifies novel host factors as potential therapeutic targets for SARS-CoV-2 infection.	O
21	In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters. 2023 , 91, 104561	O
20	Dataset on DNA methylation and gene expression changes induced by 5-aza-2?-deoxycytidine in Syrian golden hamster fetal cell cultures. 2023 , 48, 109097	O
19	Susceptibility of domestic and companion animals to SARS-CoV-2: a comprehensive review. 2023 , 55,	0
18	SARS-CoV-2 Uses Nonstructural Protein 16 To Evade Restriction by IFIT1 and IFIT3. 2023 , 97,	O
17	Mouse-Adapted SARS-CoV-2 MA10 Strain Displays Differential Pulmonary Tropism and Accelerated Viral Replication, Neurodissemination, and Pulmonary Host Responses in K18-hACE2 Mice. 2023 , 8,	0
16	Host Response of Syrian Hamster to SARS-CoV-2 Infection including Differences with Humans and between Sexes. 2023 , 15, 428	O
15	Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting. 14,	1
14	Use of the particle agglutination/particle agglutination inhibition test for antigenic analysis of SARS-CoV-2. 2023 , 17,	O
13	Animal Models, Zoonotic Reservoirs, and Cross-Species Transmission of Emerging Human-Infecting Coronaviruses. 2023 , 11, 1-31	1
12	Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review. Volume 14, 159-187	O
11	Identification of SARS-CoV-2 Mpro inhibitors containing P1I4-fluorobenzothiazole moiety highly active against SARS-CoV-2. 2023 , 14,	0
10	SARS-CoV-2 in animals: susceptibility of animal species, risk for animal and public health, monitoring, prevention and control. 2023 , 21,	1
9	Severe Acute Respiratory Syndrome Coronavirus 2 Vasculopathy in a Syrian Golden Hamster Model. 2023 ,	О
8	Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies. 2023 , 24, 5352	2

CITATION REPORT

7	Oral Administration of Universal Bacterium-Vectored Nucleocapsid-Expressing COVID-19 Vaccine is Efficacious in Hamsters. 2023 , 11,	O
6	Spatiotemporal analysis of SARS-CoV-2 infection reveals an expansive wave of monocyte-derived macrophages associated with vascular damage and virus clearance in hamster lungs.	O
5	Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. 2023 , 14,	O
4	Longitudinal analysis of SARS-CoV-2 reinfection reveals distinct kinetics and emergence of cross-neutralizing antibodies to variants of concern. 14,	O
3	Heat shock protein 90 facilitates SARS-CoV-2 structural protein-mediated virion assembly and promotes virus-induced pyroptosis. 2023 , 104668	О
2	Direct and indirect impact of SARS-CoV-2 on the brain.	O
1	SARS-CoV-2 Variant Pathogenesis Following Primary Infection and Reinfection in Syrian Hamsters.	0